STUDY OBJECTIVES: The primary aim was to determine if respiratory and skeletal muscle strength and submaximal exercise capacity were reduced in subjects prior to sibling- or unrelated-donor hematopoietic stem-cell transplantation (HSCT). DESIGN: Prospective observational study. SETTING: Tufts-New England Medical Center, a tertiary referral center in Boston, MA. PATIENTS: All patients (n = 56) undergoing either sibling- or unrelated-donor HSCT from January 1, 2002, to December 31, 2002. MEASUREMENTS: Demographic data, chemotherapy burden, pulmonary function tests (PFTs), maximal inspiratory muscle strength (PImax), maximal expiratory muscle strength (PEmax), dominant hand grip strength (GS), 6-min walk test (6MWT), and survival as of May 21, 2004. RESULTS: PImax was reduced to < 80% predicted in 42% of subjects and to < 60% predicted in 18% of subjects. PEmax was reduced to < 80% predicted in 89% of subjects and to < 60% of predicted in 80% of subjects. A significant correlation was observed between PImax and PEmax (r = 0.65, p < 0.0001). GS was reduced to < 80% predicted in 39% of subjects and < 60% predicted in 15% of subjects. The 6MWT was reduced to < 80% predicted in 58% of subjects and to < 60% predicted in 9.6% of subjects. Diffusing capacity of the lung for carbon monoxide (Dlco) was the only PFT that was significantly correlated with 6MWT distance (r = 0.44, p = 0.015). The mean calculated load of chemotherapy was 14.8 +/- 16.5 U (+/- SD). The mean time elapsed from date of hematologic diagnosis to date of HSCT was 874 +/- 1,109 days. The median survival of the cohort was 374 days (95% confidence interval, 177 to 665 days). Respiratory or skeletal muscle strength, 6MWT distance, or calculated burden of chemotherapy did not predict survival. CONCLUSIONS: Respiratory and skeletal muscle strength and submaximal exercise capacity are reduced in a significant percentage of patients prior to undergoing HSCT. These observations may help explain musculoskeletal weakness that has been reported in the posttransplant period.
STUDY OBJECTIVES: The primary aim was to determine if respiratory and skeletal muscle strength and submaximal exercise capacity were reduced in subjects prior to sibling- or unrelated-donor hematopoietic stem-cell transplantation (HSCT). DESIGN: Prospective observational study. SETTING: Tufts-New England Medical Center, a tertiary referral center in Boston, MA. PATIENTS: All patients (n = 56) undergoing either sibling- or unrelated-donor HSCT from January 1, 2002, to December 31, 2002. MEASUREMENTS: Demographic data, chemotherapy burden, pulmonary function tests (PFTs), maximal inspiratory muscle strength (PImax), maximal expiratory muscle strength (PEmax), dominant hand grip strength (GS), 6-min walk test (6MWT), and survival as of May 21, 2004. RESULTS: PImax was reduced to < 80% predicted in 42% of subjects and to < 60% predicted in 18% of subjects. PEmax was reduced to < 80% predicted in 89% of subjects and to < 60% of predicted in 80% of subjects. A significant correlation was observed between PImax and PEmax (r = 0.65, p < 0.0001). GS was reduced to < 80% predicted in 39% of subjects and < 60% predicted in 15% of subjects. The 6MWT was reduced to < 80% predicted in 58% of subjects and to < 60% predicted in 9.6% of subjects. Diffusing capacity of the lung for carbon monoxide (Dlco) was the only PFT that was significantly correlated with 6MWT distance (r = 0.44, p = 0.015). The mean calculated load of chemotherapy was 14.8 +/- 16.5 U (+/- SD). The mean time elapsed from date of hematologic diagnosis to date of HSCT was 874 +/- 1,109 days. The median survival of the cohort was 374 days (95% confidence interval, 177 to 665 days). Respiratory or skeletal muscle strength, 6MWT distance, or calculated burden of chemotherapy did not predict survival. CONCLUSIONS: Respiratory and skeletal muscle strength and submaximal exercise capacity are reduced in a significant percentage of patients prior to undergoing HSCT. These observations may help explain musculoskeletal weakness that has been reported in the posttransplant period.
Authors: Karen L Syrjala; Jean C Yi; Samantha B Artherholt; Allison C Stover; Janet R Abrams Journal: J Cancer Surviv Date: 2010-05-08 Impact factor: 4.442
Authors: Jerry Tran; Emily E Norder; Philip T Diaz; Gary S Phillips; Pat Elder; Steven M Devine; Karen L Wood Journal: Biol Blood Marrow Transplant Date: 2012-01-30 Impact factor: 5.742
Authors: J Wiskemann; R Kuehl; P Dreger; R Schwerdtfeger; G Huber; C M Ulrich; D Jaeger; M Bohus Journal: Bone Marrow Transplant Date: 2013-12-09 Impact factor: 5.483
Authors: Clarissa Vasconcellos de Souza; Eliana Cristina Martins Miranda; Celso Garcia; Francisco José Penteado Aranha; Cármino Antonio de Souza; Afonso Celso Vigorito Journal: Rev Bras Hematol Hemoter Date: 2012
Authors: Maxi Kramer; Pia Heussner; Philipp Y Herzberg; Holger Andree; Inken Hilgendorf; Malte Leithaeuser; Christian Junghanss; Mathias Freund; Daniel Wolff Journal: Support Care Cancer Date: 2012-11-01 Impact factor: 3.603
Authors: Ana Luiza Machado Dias; Mateus Camaroti Laterza; Pedro Augusto de Carvalho Mira; Isabelle Magalhães Guedes Freitas; Patrícia Fernandes Trevizan; Daniel Godoy Martinez; Leonardo Barbosa de Almeida Journal: Support Care Cancer Date: 2020-11-27 Impact factor: 3.603